ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS

Detaylı Bibliyografya
Asıl Yazarlar:	Adams, R, Maughan, T, Smith, C, Seymour, M, Wilson, R, Meade, A, Fisher, D, Madi, A, Kenny, S, Wasan, H, Rogers, P, Hodgkinson, E, Jasani, B, Cheadle, J, Kaplan, R
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	2009

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
Yazar:: Maughan, T, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
Yazar:: Adams, R, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
Yazar:: Maughan, T, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
Yazar:: Maughan, T, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
Yazar:: Madi, A, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
Yazar:: Madi, A, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Yazar:: Maughan, T, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL
Yazar:: Madi, A, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
Yazar:: Wasan, H, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
Yazar:: Adams, R, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS
Yazar:: Adams, R, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Yazar:: Adams, R, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
Yazar:: Adams, R, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RAS STATUS
Yazar:: Vale, C, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
Yazar:: Vale, C, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

HIGH THROUGHPUT SOMATIC PROFILING OF THE RAS-RAF-MAP AND PI3K-PTEN-AKT PATHWAYS IN ADVANCED COLORECTAL CANCER AND CORRELATIONS WITH RESPONSE TO CETUXIMAB
Yazar:: Smith, C, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
Yazar:: Taieb, J, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
Yazar:: Wood, G, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
Yazar:: Smith, C, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab
Yazar:: Madi, A, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
Yazar:: Seymour, M, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
Yazar:: Elli Narvi, ve diğerleri
Baskı/Yayın Bilgisi: (2018-11-01)

FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS and NRAS
Yazar:: Adams, R, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Design and development of information portal for Asian Communication Resource Centre (ACRC).
Yazar:: Yohanes Ramli.
Baskı/Yayın Bilgisi: (2008)

Role for nucleotide-excision repair gene variants in oxaliplatin-induced peripheral neuropathy
Yazar:: West, H, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Yazar:: Seymour, M, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
Yazar:: Bai L, ve diğerleri
Baskı/Yayın Bilgisi: (2019-12-01)

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
Yazar:: Madi, A, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
Yazar:: Susan D. Richman, ve diğerleri
Baskı/Yayın Bilgisi: (2011-01-01)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Yazar:: Seymour, M, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
Yazar:: J. M. Short, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

Oxaliplatin-Loaded Chitosan Nanoparticles Decorated with Cetuximab Single-Chain Variable Fragment for Human Colorectal Cancer Treatment
Yazar:: Khadijeh Falahzadeh, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
Yazar:: Akari Hashimoto, ve diğerleri
Baskı/Yayın Bilgisi: (2014-05-01)

Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
Yazar:: Moe, M, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
Yazar:: Maughan, T, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer
Yazar:: Gray, V, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
Yazar:: John Pradeep Veluchamy, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
Yazar:: Wing-Lok Chan, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

A NOVEL COLORECTAL CANCER SUSCEPTIBILITY SNP IN THE EIF3H PROMOTER INFLUENCES PATIENT SURVIVAL AND RESPONSE TO TREATMENT
Yazar:: Cheadle, J, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
Yazar:: Erik J. vanHelden, ve diğerleri
Baskı/Yayın Bilgisi: (2019-11-01)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS

Benzer Materyaller

Benzer Materyaller